Back to Dashboard
26

ACLX

🏥 Healthcare

Arcellx, Inc.

Conservative #1199Aggressive #1243Moderate RiskMixed 58
$113.76+0.01%
Day High$113.86
Day Low$113.70
Volume8.7M
Mkt Cap$6.6B
52W Low $4852W High $114
Market Cap
$3.7B
P/E Ratio
N/A
Rev Growth
-2.2%
Sector avg: 161.5%
Earnings Growth
-51.9%
Profit Margin
-607.0%
Sector avg: -3292.7%
Debt/Equity
0.12

Why This Score

ACLX scores 26.5 on the Conservative profile, blending a fundamental score (80% weight, emphasizing quality and stability (84% of fundamental weight)) with a machine-learning signal (20% weight) trained on 82 features across 30 years of data.

No material penalties applied. ACLX ranks #1199 based on its factor profile and ML signal alignment.

Score Breakdown

Overall Score26.5
Fundamental Score32.7
ML Score21.0

Score by Horizon

3 Month
26.3
6 Month
29.4
Primary
1 Year
30.9

Quality Assessment

D
Earnings Grade
Weak fundamentals or significant quality concerns
Quality Flags
Pipeline concentration: $3.7B biotech/pharma — limited product diversification
Speculative Classification
Anomalous margin data — extreme values suggest one-time events or accounting irregularities.
Conservative score reduced by 4 points.

Position Sizing

Suggested Allocation
5%
Confidence
high

Score Composition Waterfall

How each component affects the final score
Backtested Scoring Levers (IC-calibrated from 30y ElasticNet)
Weinstein (12.1%)
100
Advancing
Sentiment (2.5%)
49
Neutral
Analyst (6.4%)
75
Favorable
Tradability (post-hoc)
89
Grade A
Base
26.3
SHAP
+0.6
Factors
-0.4
Final
26.5
Positive adjustment
Negative adjustment
Base blend
Final score

Signal SegmentsComputed from ML features

Fundamental (Valuation, Quality, Growth)40.0
Technical (Momentum, Weinstein, Volatility)50.0
External (Sentiment, Analyst, Macro)56.0
Scores below 50 indicate weakness in that segment relative to the universe.

Data Quality

Score
Features
Confidence
Feature Coverage89%

Growth Estimates

Short-term
-22.3% to -12.0%
Medium-term
-29.1% to -14.6%
Long-term
-36.0% to -17.3%

ML Model Core Features100 trained inputs → ML Score: 21

These features are direct inputs to the machine learning model. The model was trained on these signals alongside 100 features (including 12 momentum/technical indicators) to produce the ML percentile score.

Analyst Intelligence
Consensus Score75.0/100
Target Upside-4.4%
Coverage14 analysts
Market Sentiment
Sentiment Score49.2/100
News Volume1 articles
Technical Stage
Weinstein Stage2 — Advancing
12M Momentum+0.1%
6M Momentum-0.0%
Volatility+0.1%
Momentum & Technical
Momentum Acceleration+7.0%
Momentum ConsistencyDivergent (-0.23)
Relative Strength vs Sector-18.7%
Trend Strength (ADX Proxy)Weak (0.6)
Momentum Quality+0.041
Momentum BreadthNarrow
Macro Regime
Bull RegimeYes
High Vol RegimeNo
S&P 500 Return+25.0%
Yield Curve-0.1bp

Sector-Relative AnalysisIn-model features

Value Trap Signal
12%
Low risk
Sector RevGr Rank
P16
Revenue growth vs Healthcare peers
Sector PE Rank
P40
Valuation vs Healthcare peers
Sector FCF Rank
P35
Free cash flow vs Healthcare peers
Growth Deviation
-0.0σ
Z-score vs sector median
Stagnation Flag
NO
Not flagged

Analysis Signals

Scoring Factors
Fundamental score of 53 relative to sector peers53/100
Machine learning model ranks this stock at the 39th percentileP39
ML model weight reduced to 9% due to macro conditions: market in extended rally phase; yield curve inverted (recession indicator); late-cycle economic indicators detected9% ML weight
SHAP feature alignment: +0.6pt (features align with model priorities)
Blend: 91% fund (52.7) + 9% ML (38.2) + SHAP(+0.6) = 52.0
Factor quality: -0.4pt (multi-factor composite)
Risk assessment: moderate. Annualized volatility 9.4%. Max drawdown 28% (-7.9 pts)Moderate
Market cap adjustment: +0.5 points ($3.7B market cap)+0.5 pts
Risk Factors
Earnings quality grade D: weak earnings quality, multiple concerns. Score adjusted by -28 pointsGrade D
Quality concern: Non-operating gain: net margin (-607.0%) exceeds operating margin (-675.7%) by 69pp — likely one-time item; Pipeline concentration: $3.7B biotech/pharma — limited product diversificationFlag

Sector Peer Comparison(Healthcare — Rank #250 of 344 stocks)

StockScoreP/ERev GrowthMarginMkt Cap
ACLX26.5N/A-2.2%-607.0%$3.7B
INCY89.615.821.2%25.0%$20.1B
GMAB85.513.122.8%36.4%$18.5B
CPRX82.213.723.5%37.6%$3.0B
VRTX78.032.18.9%32.9%$126.0B
ASND75.716.698.0%-31.7%$13.3B
NBIX74.726.521.4%16.7%$12.5B
ALKS74.616.5-6.4%23.9%$5.5B
AMGN73.826.010.0%21.0%$199.0B
ARGX73.635.178.6%38.0%$50.9B
HOLX73.331.11.7%13.8%$16.8B
REGN72.719.41.0%31.4%$84.9B
ISRG72.361.720.5%28.4%$172.5B
EXEL71.915.17.0%33.7%$11.7B
KRYS71.041.4473.0%30.7%$8.0B
HALO70.216.822.4%43.7%$9.3B
Sector Average37.1252.3161.5%-3292.7%

Market Sentimentvia FMP

Price Target
$110consensus
Low $82Median $115High $120
-2.9% to consensus target

Technical Picturecomputed from daily prices

RSI (14)
83.0
Overbought
Trend
Bullish
10-day vs 50-day MA
From 52W High
-0.4%
High: $114.26
From 52W Low
+137.7%
Low: $47.86
Moving Averages
10-Day
$81.80
Above
20-Day
$75.10
Above
50-Day
$69.90
Above
200-Day
$72.80
Above
60-Day Support
$60.36
60-Day Resistance
$114.26
Weinstein Stage Analysisbased on 200-day SMA framework
Stage 2 — AdvancingScore: 89/100

Stock is in an uptrend above the 200-day moving average. This is the stage where institutional accumulation typically occurs. The 50-day SMA provides support.

Favorable technical position; 50-day SMA acts as support
Transition signal: 1→2
Price vs 200 SMA
+56.3%
200 SMA Slope (60d)
+2.35%
Rising
Volume Ratio
3.23x
10d avg vs 50d avg
Days in Stage
3
Confidence: 50%
Breakout Volume ConfirmedRecent Gap Up

Financial Statementslast 4 quarters via FMP

MetricQ3 2025Q2 2025Q1 2025Q4 2024
Revenue$5M$8M$8M$15M
Gross Profit$-30M$8M$8M$15M
Operating Income$-62M$-59M$-69M$-53M
Net Income$-56M$-53M$-62M$-47M
EPS (Diluted)$-0.99$-0.94$-1.13$-0.88
Gross Margin-609.0%100.0%100.0%100.0%
Operating Margin-1248.3%-777.4%-847.6%-348.2%
Net Margin-1127.1%-698.6%-766.0%-308.4%

Why This Stock

Healthcare

Tradability FilterGrade A — 89/100Score impact: -6.6pt

Volume
100
1.1M avg/day
Dollar Vol
100
$123M/day
Float
69
39M shares
Mkt Cap
71
$3.7B
Range
100
139% spread
Composite Liquidity Score89/100
FDCBA

Multi-Year Range Analysis

Sideways: 0/100
YearLowHighRangeStatus
2022$6.04$33.99139.7%Wide
2023$26.32$59.1076.8%Wide
2024$47.88$107.3776.6%Wide
2025$47.86$94.0765.1%Wide
3-Year Range
121.3%
Narrow Years
0 / 4
Sideways Penalty
None

Growth Projection Adjustment

0.11x dampening
weinstein decliningslight revenue decline

Growth estimates have been dampened based on technical and fundamental signals. This is a post-hoc adjustment to prevent overly optimistic projections for stocks showing declining momentum or deteriorating fundamentals.

Free Float
67.0%
Outstanding Shares
58M
Bid-Ask Spread
139.0%
Institutional Tradable
Yes

Scores are generated by a multi-stage ML pipeline combining fundamental analysis, ensemble predictions, and structural risk signals. All data is for research purposes only and does not constitute financial advice. Past performance does not guarantee future results.